InMed completes name change to Mentari, 1-for-10 consolidation, discloses Series A preferred terms

InMed Pharmaceuticals Inc. held its annual general and special meeting on November 4, 2026, where every item of business put before shareholders was approved. A total of 3,630,088 common shares, representing approximately 66.08% of the company's 5,493,735 issued and outstanding shares, were represented in person or by proxy.¹

Shareholders approved the Nasdaq Share Issuance Proposal tied to the merger agreement with Mentari Therapeutics, Inc., a Delaware corporation, by a vote of 97.295% in favor, along with a return of capital proposal, redomestication to Nevada, the 2026 Stock Incentive Plan, the 2026 Employee Stock Purchase Plan, merger-related executive compensation, and election of five directors including Andrew Hull, Nicole Lemerond, Neil Klompas, John Bathery and Eric A. Adams.

Following the meeting, the company's board approved a change of the Company's corporate name to "Mentari Therapeutics, Inc." and approved a consolidation of the Company's common shares on a one (1)-for-ten (10) basis¹, which was filed with British Columbia's registrar effective November 4, 2026. Every ten common shares issued and outstanding immediately prior to the consolidation were automatically consolidated into one issued and outstanding common share, without any change in shareholders' proportionate equity or voting interests¹, reducing total shares to approximately 549,374. Shares are expected to begin trading on Nasdaq on a post-consolidation basis starting November 5, 2026 under the symbol "INM," with new CUSIP 457637809 and ISIN CA4576378091.

The filing also disclosed new preferred stock terms. The Notice of Alteration designated 4,013 of the company's authorized but undesignated preferred shares as Series A Non-Voting Preferred Shares, effective November 4, 2026.¹ These shares carry no general voting rights apart from electing two directors while at least 30% of the originally issued Series A Preferred Shares remain outstanding, and each share converts into 1,000 common shares, subject to a 19.99% beneficial ownership cap.¹

The company also expects to issue one contingent value right for each outstanding common share to holders of record as of the close of business on November 5, 2026¹, with closing of the merger still subject to satisfaction or waiver of conditions in the merger agreement.